Second Generation Antipsychotics and Cardiovascular Adverse Effects: Developing Evidence-Based Recommendations for Primary Care Medicine

Our project indicated that cardiovascular risks can be associated with SGAs and that screening and monitoring for cardiac toxicities are indicated when treating patients with this class of medications. These risks, however, do not appear to override benefits in most patients. Furthermore, it appears that when using SGAs, methods of risk reduction can be applied effectively in the primary care setting.